rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
Validation of the Cervicothoracic Differentiation Test
Status: Recruiting

The goal of this clinical trial is to compare the effects of two spinal manipulations in adults between the ages of 18-65 based on the results of a non-invasive clinical test. The main question it aims to answer is: • Does matched or unmatched region of manipulation based on the CTDT result in greater reduction of pain levels and improvement in range of motion in adults with neck pain compared to unmatched manipulations? Participants will be asked to:

rate their pain with neck movement, complete brief questionnaires about their pain,
have their neck range of motion measured,
perform a test known as the cervico-thoracic differentiation test (CTDT),
receive either a cervical or thoracic manipulation,
repeat the range of motion measurements.
A second session will occur 7-10 days later where questionnaires and range of motion measures will be repeated.

Researchers will compare the effects of manipulation matched to CTDT test result to individuals in the unmatched CTDT manipulation group to see if the CTDT may indicate which region will provide a greater treatment effect for individuals with neck pain.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  between the ages of 18 and 65, must report neck pain with a Visual Analogue Scale (VAS) greater than or equal to 3/10.  Exclusion Criteria:  History of motor vehicle accident (MVA) within the past 6 months, hypertension greater than or equal to 160/100, non-mechanical neck pain (pain that is not reproducible with movement), any past or present history of cancer, upper motor neuron (CNS) lesion symptoms ( a positive Clonus sign, Babinski sign, or hyperreflexia of DTR's), any infection that originates from the spine Current confirmed or suspected pregnancy, or recent postpartum (6 mos), known osteoporosis, rheumatoid arthritis, long-term use of corticosteroids (>6mos), history of neck surgery, history of vertebral or rib fractures, blood clotting disorders, connective tissue disorders, radicular/neural pain/symptoms. Radicular pain and symptoms would include dermatomal changes (sensory loss or hypersensitization), myotomal changes (weaknesses of muscular along nerve distributions), decreased reflexes (hyporeflexia), pain that travels down the upper extremities, and pain that is referred into the upper extremities. clinical signs of instability of the vertebral segments in their neck - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
Status: Not yet recruiting

To learn about the safety of giving the drug brexucabtagene autoleucel to participants with relapsed/refractory B-cell ALL after treatment with inotuzumab ozogamicin, blinatumomab, and either hyper-CVAD or mini-hyper-CVD. Also, to learn if giving brexucabtagene autoleucel to patients with relapsed/refractory or high-risk, newly diagnosed B-cell ALL after treatment with inotuzumab ozogamicin, blinatumomab, and either hyper-CVAD or mini-hyper-CVD can help to control the disease.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  I. Participants of age ≥18 years with documented relapsed or refractory B-cell ALL  II. In the newly diagnosed cohort: Participants of age ≥18 years with high-risk newly diagnosed B-cell ALL defined as:  KMT2A rearranged ALL Complex cytogenetics as per NCCN 2022 Low-hypodiploidy/tetraploidy Philadelphia-like ALL (based on CRLF2 overexpression or recurrent Ph-like genetic fusions)  III. Performance status of 0, 1, or 2  IV. Adequate organ function with creatinine less than or equal to 1.6 mg/dl, bilirubin less than or equal to 3.5 mg and ALT and AST less than or equal to 5 times institutional upper limit of normal  V. Participants should be CD19 expression positive (>50%) before enrollment  Exclusion Criteria  Philadelphia positive B-cell ALL Pregnant or lactating; women of child-bearing potential (WOCBP) must have negative pregnancy test. WOCBP defined as not post-menopausal for 12 months or no previous surgical sterilization Prior exposure to brexu-cel or other anti-CD-19 CAR T cell therapy Known HIV-positive participants Active and uncontrolled disease/infection as judged by the treating physician Unable or unwilling to sign the consent form No other investigational therapy within the past 14 days - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Preliminary Evaluation of a Mental Health Program: a Comparison Study
Status: Not yet recruiting

The mental hygiene challenge is a Royal Ottawa Health Care Group led initiative to engage the staff, clients and community members to attend to their mental well-being by way of practicing mental hygiene activities for 10 min on a daily basis, throughout the month of March. Participants are encouraged to choose one or many of the practices recommended and do them for about 10 minutes a day. Participants are encouraged to make it their own, in that they can combine the practice or tailor them in a way that suits them best. When signing up for the challenge, participants receive free access to a toolkit with brief outlines and instructional videos on various mental hygiene practices.

We also encourage participants to divide the 10 minutes in whatever way best works for them, such as 10 minutes all at once, 5 minutes twice, or even 2 minutes five times. This study aims to expand on the work that was done in 2022 and 2023, when the World Health Organization - 5 Wellbeing Index (WHO-5) and the Warwick Edinburgh Mental Wellbeing Scale (WEMWBS) were collected from participants to ascertain the impact of mental hygiene, by way of including a control group.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  18 years and above can speak English  Exclusion Criteria:  Have previously participated in the mental hygiene challenge before (exclusion for the control group). - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Novel Prevention Intervention Program to Reduce Risky Patterns of Substance Use Among Emerging Adults
Status: Not yet recruiting

The purpose of this research study is to test whether completion of a new personalized feedback program is associated with reductions in risky substance use among emerging adults (18-25 years of age).

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  This study is for emerging adults between 18-25 years who reside in the United States. These individuals must also be English-speaking.  Exclusion Criteria:  Participants will be excluded from the study if they are younger than 18 years old, older than 25 years old, reside outside of the United States, or if they do not provide informed consent. These exclusion criteria have been chosen because we are targeting emerging adults (a particularly risky population in terms of substance use behaviors). - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - MaximumAge: 25 Years - StdAgeList: Adult
Assessment of Self-Confidence of Dental Interns Regarding Provision of Different Pediatric Dentistry Procedures
Status: Not yet recruiting

This study mainly about dental interns testing their knowledge before and after entering the pediatric rotation

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Dental interns who got their bachelor's degree from Egyptian governmental and private universities. Dental interns who passed the internship period in the pediatric dentistry department.  Exclusion Criteria:  Dental interns who got their bachelor's degrees from abroad universities. - Gender: All - StdAgeList: Child, Adult, Older Adult - StudyPopulation: Dental interns who are taking their internship at the Cairo university - SamplingMethod: Probability Sample
Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Inclisiran in Italy
Status: Recruiting

Evaluation of adherence, persistence and efficacy of treatment with Inclisiran in a real-life Italian population

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients under Inclisiran treatment  Exclusion Criteria:  Age < 18 years o > 80 years Patients who refuse to participate and to sign informed consent - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: The study population includes patients from Italy, who have received Inclisiran as part of routine clinical management of their hyperlipidaemia, based on national reimbursement criteria, at time of enrollment - SamplingMethod: Probability Sample
Management of Heart Failure in Italian Outpatients Clinics: Observational Study
Status: Recruiting

OPTIMA-HF is an observational, cross-sectional, multicenter, real-life study conducted in two different clinical settings: HF outpatients' clinics of Italian University Hospitals and territorial Cardiology outpatients' services.

Aim of the Optimization of Therapy in the Italian Management of Heart Failure [OpTIMa-HF] Registry is to collect data on HF patients followed in different Italian outpatients' settings to describe the current Italian population of HF patients, in terms of demographic characteristics and disease features, with a specific focus on guideline-directed medical therapy (GDMT) prescription, assessing its improvement after educational activities. In the present analysis we report the baseline data on the general enrolled population with a specific focus on HFrEF treatment adherence and prescription rates, according to the most recent European Guidelines.

Eligibility:
- EligibilityCriteria: Inclusion Criteria: age >18 years, post-menopausal, permanent sterile, or childbearing potential on highly effective contraceptive methods women, stable clinical conditions (NYHA class I-III), outpatients setting, capability to understand the study procedures and sign the informed consent form.  Exclusion Criteria: any clinical condition that would have jeopardized patient safety while participating in this study. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: HF patients in stable clinical conditions - SamplingMethod: Non-Probability Sample
Regional Anesthesia EMG Study
Status: Recruiting

This study aims to investigate how non-invasive, non-significant risk EMG monitoring can be used intraoperatively to objectively characterize neuraxial anesthesia (i.e. spinal and caudal blockade) in pediatric patients undergoing surgery. The investigators will also attempt to measure the effect of adjunctive intrathecal clonidine on spinal and caudal blockade using EMG. This study also aims to quantify the impact of sevoflurane on basal muscle tone based on EMG changes. This study aims to generate pilot data on this subject to help design future studies.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Group 1 (GA + penile block): age 5 years or below getting: circumcision or circumcision revision Group 2-5 (SA or GA + CA): age 5 years or below getting: penile or scrotal surgery, inguinal hernia repair, Achilles tendon lengthening, other applicable urological procedures Group 6 (GA only): age 5 years or below getting: operative dentistry, urological or ENT procedures  Exclusion Criteria:  parent refusal systemic infection spine or CNS abnormalities medication allergy adhesive allergy - HealthyVolunteers: No - Gender: All - MinimumAge: 0 Years - MaximumAge: 5 Years - StdAgeList: Child
The Effect of Ciprofol on Breathing Patterns, Respiratory Drive, and Inspiratory Effort in Mechanically Ventilated Patients
Status: Recruiting

Sedatives and analgesics are usually given for analgesic, anxiolytic, or sedating purposes for patients with critical illness, while they inevitably inhibit respiratory and circulatory function. Sometimes, patients receive deep sedation to induce hypoventilation or suppress spontaneous respiratory effort. The sedation level in clinical practice is usually assessed with subjective sedation scoring systems, such as the Richmond Agitation Sedation Scale (RASS). However, studies have found that sedation depth based on RASS is not a reliable marker of respiratory drive during critical illness. In recent years, researchers have proposed to monitor the effects of sedatives and analgesics on respiratory indicators and to implement lung-protective sedation, such as P0.1, Pocc, Pmus, WOB, and PTP. However, different pharmacological characteristics, different depths of sedation, and different sedation regimens among different sedatives and analgesics make a great difference in their effects on respiration. Ciprofol is an analog of propofol, with increased stereoselective effects adding to its anesthetic properties, is increasingly used in the intensive care unit, but its effects on respiration are not well understood. Therefore, this study aims to investigate the effects of ciprofol on respiratory patterns, respiratory drive, and inspiratory effort in mechanically ventilated patients.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  The patient received surgery under general anesthesia and admitted into the ICU The patient has been intubated and is receiving invasively mechanically ventilated with the mode of pressure support (PSV) or continuous positive airway pressure (CPAP) The patient requires sedative medication targeting RASS -2 to +1 for comfort, safety and to facilitate the delivery of life support measures  Exclusion Criteria:  Age < 18 years Body mass index (BMI) <18 or >30 kg/m2 Pregnancy or lactation Brain stem tumors, myasthenia gravis, or neuromuscular diseases Acute severe neurological disorder and any other condition interfering with RASS assessment Systolic blood pressure < 90 mmHg after appropriate intravenous volume replacement and continuous infusions of 2 vasopressors Heart rate < 50 beats per minute or second- or third-degree heart block in the absence of a pacemaker Contraindicate or allergic to any of the study medications Acute hepatitis or serious hepatic dysfunction (Child-Pugh class C) Chronic kidney disease with glomerular filtration rate (GFR) < 60 ml/min/1.73m2 Alcohol abuse - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Renal Assessment for Early Detection of Renal Impairment in Systemic Sclerosis and Systemic Lupus Erythematosus Patients
Status: Not yet recruiting

Evaluate renal resistive index in SSc and SLE patients for early detection of renal impairment.
Evaluate renal multi-parametric MRI in SSc and SLE patients for early detection of renal impairment.
Measure the serum levels of CD147 in SSc and SLE patients and its correlation with renal impairment.
Correlation between detected markers and other assessment tools.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Adult (aged above 18 years) SSc patients who fulfilled the 2013 European League Against Rheumatism/American College of Rheumatology (EULAR / ACR) for SSC [13] and 1980 ACR criteria [14]. Adult SLE Patients who fulfilled the 2019 EULAR / ACR classification criteria for systemic lupus erythematosus [15]  Exclusion Criteria:  Individuals with other autoimmune diseases. Smoking. Infections as chest infection, hepatitis C, hepatitis B and HIV infection. Tumors as hepatocellular carcinoma. Hypertension, diabetes, heart failure, hepatic diseases, chronic renal failure, intrarenal arteriovenous fistula, obstructive nephropathy and urinary tract obstruction. Contraindication for MRI as implanted metallic devices. - Gender: All - MinimumAge: 18 Years - MaximumAge: 70 Years - StdAgeList: Adult, Older Adult - StudyPopulation: The study will include adult SSc and SLE patients consecutively presented at the rheumatology, rehabilitation and physical medicine department, Assiut university hospital from both inpatient department and outpatient clinic - SamplingMethod: Non-Probability Sample
Prevention of Acute Cholecystitis With ETGBD
Status: Not yet recruiting

The goal of this clinical trial is to learn about Efficacy of the ETGBD parallel insertion with fully covered self-expandable metal stent for preventing acute cholecystitis in patients with low cystic duct insertion.

In this study, we hypothesized that endoscopic transpapillary gallbladder drainage (ETGBD) with parallel insertion of a fully covered self-expanding metal stent(FCSEMS) through an endoscopic biliary drainage tunnel is superior in preventing complications such as cholecystitis when the gallbladder ducts confluence within the distal third of the common bile duct. And we aimed to confirm its efficacy by comparing the frequency, severity, and rate of invasive additional procedures due to cholecystitis complications to provide evidence of clinical utility.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Adults 19 years of age or older Patients requiring endoscopic retrograde cholangiography and drainage for therapeutic purposes. Patients with imaging (CT, Cholangiogram) confirmed confluence of the cystic duct with the distal third of the common bile duct. Patients who have voluntary informed consent to participate in the study.  Exclusion Criteria:  Patients who have undergone percutaneous/surgical bile duct or gallbladder drainage prior to study enrollment. Patients with anatomic deformity of the upper gastrointestinal tract after gastric or hepatobiliary surgery Patients with concomitant gastric/duodenal obstruction Patients with confirmed or suspected cystic duct obstruction on imaging studies Patients with acute cholecystitis, acute pancreatitis Patients who underwent cholecystectomy Patients with a life expectancy of less than 3 months Patients who are otherwise unable to undergo endoscopic retrograde cholangiopancreatography - HealthyVolunteers: No - Gender: All - MinimumAge: 19 Years - StdAgeList: Adult, Older Adult
JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)
Status: Not yet recruiting

The primary objective is to monitor the safety profile of JARDIANCE® in Korean patient with chronic kidney disease (CKD) in routine clinical practice.

The secondary objective is to monitor the efficacy of JARDIANCE® by evaluating changes in urine albumin-creatinine ratio (UACR) after 12 and/or 24 weeks of treatment.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age ≧19 years at enrolment Patients diagnosed with CKD Patients with CKD starting JARDIANCE® for the first time in accordance with the approved label in Korea Patients who have provided informed consent and signed the data release consent form  Exclusion Criteria:  Patients with previous exposure to JARDIANCE® Patients with hypersensitivity to empagliflozin or to any of the excipients Patients with type 1 diabetes Patients with history of Diabetic Ketoacidosis (DKA) Patients on dialysis Patients with rare hereditary conditions of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption Patients who are pregnant or are breastfeeding or who plan to become pregnant during the study period - HealthyVolunteers: No - Gender: All - MinimumAge: 19 Years - StdAgeList: Adult, Older Adult - StudyPopulation: This is a single-arm, open-label, multi-centre observational and non-interventional study (ONIS) based on newly collected data. This study will be carried out by enrolling patients in a consecutive manner into the study requiring completion of case report forms (CRFs) for all participants who initially administered JARDIANCE® following the study start date until the planned number of participants is reached. - SamplingMethod: Probability Sample
Bleaching Effect of Strawberry Extract Versus Hydrogen Peroxide in Patients With Extrinsic Staining
Status: Not yet recruiting

with limited evidence based information in literature about using Strawberry extract for teeth bleaching in patients with extrinsic staining , it is beneficial to evaluate this new material using a randomized controlled clinical trial to test the null hypothesis that this extract will have the same effect as Hydrogen peroxide regarding the bleaching effect and hypersensitivity.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Participant inclusion criteria:  At least 18 years old. Good general and oral health. six present maxillary anterior teeth.  Tooth inclusion criteria:  yellowing of teeth due to age. stains due to coffee or tea.  light tetracycline stain.  Exclusion Criteria:  participant exclusion criteria:  patients undergoing radiotherapy or chemotherapy. Pregnant females or breast feeders. Bruxism and patients who reported tooth sensitivity.  Tooth exclusion criteria:  Hypoplastic enamel. carious lesion. sensitive recession area or sensitive tooth. Amalgam staining. Non vital tooth. Discolration due to pulp trauma or necrosis. presence of non carious cervical lesion. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
The Role of the Free/Pedunculated Flap in Total Laryngectomy After (Chemo-)Radiotherapy Failure for Laryngeal Carcinoma: Impact on the Risk of Pharyngocutaneous Fistula (PCF)
Status: Recruiting

Multicenter, prospective, randomized study aimed at evaluating the difference in risk of PCF after salvage laryngectomy in two groups of patients: one cohort treated with Total Laryngectomy (LT) with primary suture, a second group treated with LT and reinforcement by flap positioning with onlay technique (PMM, ALT)

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Histological confirmation of recurrence/persistence of squamous cell carcinoma of the larynx previously subjected to exclusive radiotherapy or concomitant chemo-radiotherapy treatment:  pre (ChT-)RT staging: cT1/T2/T3 N0/N+; pre STL staging: rcT1/cT2/ Selected cT3 cT4a (extension to thyroid cartilage and/or prelaryngeal tissues) N0/N+ (clinically and radiologically). Indication for STL surgery (no pharyngeal mucosal resection); Functional total laryngectomies after radical (chemo-)radiotherapy treatment; Age > 18 years; Signature of informed consent and ability to complete in-office questionnaires.  Exclusion Criteria:  STL extended to the pharynx and/or total pharyngeal laryngectomies; Extension of the tumor to the pharyngeal mucosa and/or massive extra-laryngeal extension; Previous open organ preservation surgery (OPHL). - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients suffering from recurrence/persistence of laryngeal SCC following exclusive RT treatment or concomitant RT/ChT without extension to the pharynx (rcT1/T2/T3 selected rcT4a N0/N+) who will have to undergo STL and who will meet the following criteria. Patients undergoing extensive laryngectomies or with disease with even partial involvement of the pharyngeal mucosa (pyriform sinus, posterior wall of the pharynx) will not be included. - SamplingMethod: Non-Probability Sample